BioBiz Buzz

https://biobizbuzz.com/
  • 0.0 (0)
  • NEWS COMMENTARY

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.  Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.    Disclaimer https://biobizbuzz.com/disclaimer/

  1. 21. Targeting What Others Miss: How HaemaLogiX Is Tackling Multiple Myeloma's Toughest Challenges

    5H AGO

    21. Targeting What Others Miss: How HaemaLogiX Is Tackling Multiple Myeloma's Toughest Challenges

    Multiple myeloma remains the second-largest blood cancer globally with no cure, and despite recent breakthroughs in CAR-T and antibody therapies, patients continue to relapse, often losing the very antigens that therapies target. In this episode of BioBiz Buzz, host Mike Ward speaks with Dr. Chris Baldwin, CEO and Managing Director of HaemaLogiX, an Australian clinical-stage biotech pioneering a differentiated approach to treating this devastating disease. HaemaLogiX has identified two novel antigens, kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), that are uniquely expressed on malignant plasma cells but absent from healthy immune cells, offering exquisite tumor specificity. The company's lead asset, KappaMab, has already demonstrated an 83% response rate and a 46% reduction in death risk in Phase IIb trials, while its KMA.CAR-T therapy is progressing through Phase 1 trials in partnership with the renowned Peter MacCallum Cancer Centre. Dr. Baldwin discusses the significant unmet medical need in multiple myeloma,  where median survival post-diagnosis is just five to seven years and treatment-related toxicities often devastate patients' immune systems. He explains how HaemaLogiX's approach addresses critical limitations of current BCMA-targeted therapies, including antigen loss at relapse, off-target toxicity, and immune suppression. With approximately 70% of myeloma patients expressing KMA and the remaining 30% expressing LMA, HaemaLogiX's platform could potentially treat nearly all multiple myeloma patients. Looking ahead to the company's planned ASX IPO in 2026, Dr. Baldwin outlines the strategic priorities: advancing the higher-dose Phase IIb trial of KappaMab in combination with standard-of-care therapies, enrolling and treating patients in the Peter Mac CAR-T trial, developing LambdaMab for lambda-type myeloma and AL amyloidosis, and expanding into next-generation bispecific antibodies. He also addresses the operational challenges of scaling CAR-T manufacturing, navigating competitive dynamics in the crowded immunotherapy landscape, and securing the capital needed to bring these life-saving therapies to market in a sector valued at over $23 billion annually and growing at 6-8% per year. This conversation provides essential insights for investors, clinicians, and industry stakeholders seeking to understand how differentiated science, strategic partnerships, and disciplined clinical development can position an emerging biotech to address one of oncology's most intractable diseases.  ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    30 min
  2. 20. Redefining HIV Treatment and Prevention: Gilead’s Next Chapter

    MAR 3

    20. Redefining HIV Treatment and Prevention: Gilead’s Next Chapter

    In this episode of BioBiz Buzz, your host Mike Ward sits down with Dr. Jared Baeten, Senior Vice President for Clinical Development and Head of the Virology Therapeutic Area at Gilead Sciences, to explore how new data from CROI 2026 could signal the start of a new chapter in HIV treatment and prevention.  During the discussion, they unpack Phase 3 results from the ARTISTRY‑1 and ARTISTRY‑2 trials, which evaluate BIC/LEN, an investigational single‑tablet regimen that combines the guideline‑standard integrase inhibitor bictegravir with the long‑acting capsid inhibitor lenacapavir in virologically suppressed people living with HIV, including those on complex multi‑tablet regimens.  The discussion examines what non‑inferiority to standard-of-care regimens, high rates of viral suppression, and favourable safety and satisfaction profiles could mean for an ageing, comorbid population that still struggles with pill burden, drug–drug interactions, and resistance. Mike and Jared then turn to prevention, focusing on twice‑yearly lenacapavir for PrEP, marketed as Yeztugo in the US, and the broader PURPOSE program. They look at how strong efficacy signals across diverse populations, early real‑world launch experience, and rapid access efforts in high‑burden regions may expand the overall PrEP market rather than simply cannibalise oral options. Finally, they discuss Gilead’s long‑acting pipeline vision—from weekly orals to potentially once‑yearly injectable PrEP—and how the company is balancing ambitious innovation with mounting pricing and policy headwinds while aiming to sustain HIV franchise growth into the 2030s. They also examine how access can be expanded so that people living with HIV can benefit from these medicines in both high-income and low-income countries. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    34 min
  3. 19. From Genesis to Revelations: Winners & Losers in Pharma’s Most Volatile Year

    12/18/2025

    19. From Genesis to Revelations: Winners & Losers in Pharma’s Most Volatile Year

    2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, fresh from his opening keynote at One Nucleus's landmark Genesis conference in London. Join us as Mike dissects the winners and losers reshaping pharma's landscape: Eli Lilly's historic ascent to a trillion-dollar market cap, driven by clinical superiority in the obesity space and revenues growing at 46 % year-to-date, versus Novo Nordisk's stunning $400 billion value destruction through clinical disappointments, patent losses, and execution failures. Beyond the headline-grabbing giants, discover why China has transformed from a low-cost alternative to a global innovation powerhouse, now contributing 38 % of patents in cutting-edge protein degradation technology. Explore the strategic M&A moves reshaping the industry, including the transformational Metsera bidding war and the real deal-making in Chinese oncology assets. Understand the FDA's revolutionary "Plausible Mechanism Pathway", opening new regulatory opportunities in rare disease and how AI is finally moving from hype to robust commercial valuations. This is essential listening for anyone seeking to understand the seismic shifts reshaping biopharma investment, innovation, and competitive positioning as the industry heads into 2026. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    25 min
  4. 18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them

    12/16/2025

    18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them

    Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies. The two approaches are conceptually similar – each involves the isolation and modification of patients’ T-cells to recognise and kill tumour cells. The main difference lies in the types of antigens they can recognise. Whereas CAR-T therapies are currently confined to a handful of extracellular antigens expressed on the surface of malignant (and healthy) B-cells, TCR therapies can target a whole universe of intracellular antigens, fragments of which are presented on the cell surface as peptide fragments by major histocompatibility complex (MHC) molecules. Ensuring these highly engineered cells can persist, expand and operate effectively within the immunosuppressive tumour microenvironment in patients has been a complex challenge. But the current generation of therapies is starting to show promising results. In this episode of BioBiz Buzz, Elisa Kieback, co-founder and Chief Technology Officer at T-knife Therapeutics, joins your host Cormac Sheridan to discuss how TCR cell therapies work and what they can do, and how the founders of the Berlin-based company came up with its distinctive name. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    23 min
  5. 17. Democratizing Drug Discovery: How Lilly ExploR&D Is Changing the Biotech Playbook

    12/03/2025

    17. Democratizing Drug Discovery: How Lilly ExploR&D Is Changing the Biotech Playbook

    The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships on terms controlled by Big Pharma. Tom Hopkins, VP and Head of Lilly ExploR&D, is working to flip that script.  In this episode, Tom joins your host Mike Ward to discuss the four critical barriers early-stage biotechs face (expertise gaps, data infrastructure challenges, execution risk, and capital inefficiency) and how Lilly's integrated platform of capital, expertise, and infrastructure is removing those barriers.  Learn how the future of drug discovery isn't about companies innovating in isolation, it's about removing friction and accelerating the best science from wherever it exists toward patients. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    28 min
  6. 16. The Smart Money Talks: Inside Sofinnova's Bold €650M Fundraise

    11/17/2025

    16. The Smart Money Talks: Inside Sofinnova's Bold €650M Fundraise

    In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has just closed its flagship Capital XI fund at €650 million, significantly exceeding its initial target of €500 million. What does this signal about the state of healthcare innovation funding in 2025? In this episode of BioBiz Buzz, your host Mike Ward sits down with Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, to unpack one of the most significant European life sciences venture capital announcements of the year. Together, they explore why leading pharma companies, sovereign wealth funds, and top-tier institutional investors are doubling down on early-stage biotech and medtech when the broader VC market is under pressure.  Moreover, they discuss Sofinnova's disciplined, science-driven investment strategy, the geographic and therapeutic opportunities driving Capital XI deployments, and what the €1.5 billion raised across Sofinnova's platform over the past year reveals about institutional confidence in healthcare innovation. More importantly, what does Sofinnova's oversubscription mean for the future of early-stage healthcare ventures as they head into 2026? Whether you're an entrepreneur seeking funding, an industry strategist tracking market dynamics, or an investor evaluating the early-stage healthcare landscape, this conversation provides critical insights into where the smart money is being invested and why.  ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    25 min
  7. 15. Targeting Misfolded SOD1 in ALS: A First-in-Class Antibody Shows Promise

    11/11/2025

    15. Targeting Misfolded SOD1 in ALS: A First-in-Class Antibody Shows Promise

    This episode of BioBiz Buzz explores AL-S Pharma's pioneering approach to treating amyotrophic lateral sclerosis through AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1 protein. Host Mike Ward speaks with Dr. Michael Salzmann, CEO of AL-S Pharma and COO of Neurimmune, and Professor Angela Genge, CMO of AL-S Pharma and Professor of Neurology at McGill University. The conversation examines the devastating impact of ALS, a progressive neurodegenerative disease that typically leads to death within three to five years of symptom onset, and the profound unmet need for disease-modifying therapies. Dr. Salzmann explains how AP-101 was discovered using Neurimmune's proprietary Reverse Translational Medicine platform, which leverages human immune responses to identify antibodies that selectively bind misfolded and aggregated forms of SOD1 while sparing normally folded protein. Professor Genge discusses the intriguing evidence that misfolded SOD1 may play a role not only in familial ALS patients with SOD1 mutations but also in sporadic ALS patients without known genetic causes, potentially expanding the therapeutic opportunity to a much broader patient population. The Phase 2 study enrolled 73 ALS patients, both sporadic and SOD1 mutation carriers, and met its co-primary safety and tolerability endpoints while demonstrating clinically meaningful changes in exploratory outcome measures, including survival, ventilation requirements, and neurofilament biomarkers after 12 months of treatment. The guests explore the unique collaborative ecosystem that enabled this progress, including the partnership between Neurimmune and TVM Capital Life Sciences, and discuss AP-101's Orphan Drug Designation from the FDA, EMA, and Swissmedic.  ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    32 min
  8. 14. The NanoPortal platform: Vivani Medical is reimagining how GLP-1s are delivered.

    10/30/2025

    14. The NanoPortal platform: Vivani Medical is reimagining how GLP-1s are delivered.

    GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge.  US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once inserted, patients and caregivers can be confident that the intended medicine is being delivered throughout the once- or twice-yearly dosing interval. In this episode of BioBiz Buzz, CEO and co-founder Dr. Adam Mendelsohn, discusses the company’s NanoPortal platform technology with your host Shani Alexander. The platform centers on vertically aligned titanium dioxide nanotubes, incredibly tiny, precise channels that are over 40 micrometers in length and attached to a titanium substrate. The key innovation lies in the pore sizing: when the pore is only slightly larger than the drug molecule, the system achieves near-constant, steady-rate medication delivery over many months. With chronic disease management placing a huge burden on patients - remembering doses, managing side effects and making frequent visits to clinics, the NanoPortal platform is built around a fundamental principle: to maintain steady, consistent drug levels over extended periods, to guarantee adherence and potentially improve tolerability.  Mendelsohn says that the company is reimagining how GLP-1s can be delivered. For him, the NanoPortal platform represents a fundamental shift from treatment management to treatment assurance. The technology could move the healthcare system toward a model where patients receive a simple procedure every few months and know they're getting optimal, consistent therapy, he argues. Beyond individual patient outcomes, Mendelsohn believes the platform could have massive implications for healthcare economics. Poor medication adherence costs the US healthcare system hundreds of billions of dollars annually. He explains that if patients can get the full benefit of their prescribed therapies, this can lead to both better outcomes and significant cost savings. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Disclaimer ● LinkedIn

    17 min
See All (21)

About

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.  Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.    Disclaimer https://biobizbuzz.com/disclaimer/

Information

  • Creator
    https://biobizbuzz.com/
  • Years Active
    2025 - 2026
  • Episodes
    21
  • Rating
    Explicit
  • Copyright
    © 2026 BioBiz Buzz
  • Show Website
    BioBiz Buzz